Immunotherapy: CAR T cells in glioblastoma

Nature Reviews Drug Discovery 16, 602 (2017). doi:10.1038/nrd.2017.158 Author: Crunkhorn Sarah Chimeric antigen receptor-modified T (CAR T) cells have shown efficacy in leukaemia and lymphoma. Now, O'Rourke et al. report on the first clinical trial of CAR T cells targeted to the epidermal growth factor receptor variant III (EGFRvIII) in 10 patients with recurrent glioblastoma.

http://dx.doi.org/10.1038/nrd.2017.158

Source: Nature Reviews Drug Discovery - August 11, 2017 Category: Drugs & Pharmacology Authors: CrunkhornSarah Tags: Research Highlight Source Type: research

More News: Clinical Trials | Drugs & Pharmacology | Immunotherapy | Leukemia | Lymphoma